
IQVIA Hlds (IQV) Stock Forecast & Price Target
IQVIA Hlds (IQV) Analyst Ratings
Bulls say
IQVIA Holdings is viewed positively because 3Q26 showed strong operating momentum, with R&DS net new bookings of $3.2 billion, up 15% year over year and the highest in four years, while LTM bookings rose 14% and ending backlog reached $32.6 billion. Management also raised 2026 adjusted EPS guidance to $12.90-$13.00, and the company’s mix of recurring, high-visibility clinical research and commercial analytics supports a path to about 6% revenue growth and 10% EPS growth in 2027. The bullish case is further reinforced by improving win rates, healthy demand in emerging biotech and mid-pharma, and AI-driven productivity that should enhance timelines, margins, and competitive positioning versus peers.
Bears say
IQVIA Holdings is facing a tougher competitive backdrop as large pharma procurement cycles intensify pressure across the CRO market, with mid-tier providers squeezed most between scaled global players and specialized niche firms. Its exposure to large pharma rather than emerging biotech may limit near-term growth resilience, while the broader industry remains vulnerable to biotech VC deterioration, biopharma customer consolidation, regulatory shifts, and AI disruption. The company-specific outlook is further weakened by higher-than-industry-average leverage, FX and funding uncertainty, potential slowdown in pharma spending, and execution risk around M&A, debt retirement, and clinical trial starts.
This aggregate rating is based on analysts' research of IQVIA Hlds and is not a guaranteed prediction by Public.com or investment advice.
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares
FAQs About IQVIA Hlds (IQV) Forecast
IQVIA Hlds (IQV) Analyst Forecast & Price Prediction
Start investing in IQVIA Hlds (IQV)
Order type
Buy in
Order amount
Est. shares
0 shares